Finland awards EUR 300,000 for global equality work – Zarifa Ghafari, Richard Lui and Susana Malcorra join the jury
13.9.2023 09:00:00 EEST | Business Wire | Press release
Finland celebrates gender equality by awarding the International Gender Equality Prize every two years. The prize is awarded to a person or organisation that has made a significant international contribution to gender equality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912593136/en/
Finland celebrates gender equality by awarding the International Gender Equality Prize every two years. The prize is awarded to a person or organisation that has made a significant international contribution to gender equality. In 2023, the EUR 300,000 prize amount will be awarded in a ceremony in Tampere, which has been the host city from the beginning. This year's Prize Jury includes human rights activist Zarifa Ghafari, actress Krista Kosonen, news anchor Richard Lui, co-founder and President of GWL Voices Susana Malcorra and CMI - Martti Ahtisaari Peace Foundation’s Chair of the Board Alexander Stubb. The International Gender Equality Prize is a prize awarded by the Finnish Government. Photo: Johanna Sokka
The success of Finland as a country is to a great extent linked with improvements in the status of women and gender equality. For example, Finland was the first country in the world to extend the right to vote and stand for elections to all women and men in 1906. The country has been a frontrunner in gender equality for over a century now and the award is a way to champion gender equality efforts worldwide.
In 2023, the EUR 300,000 prize amount will be awarded in a ceremony in Tampere, which has been the host city from the beginning. The International Gender Equality Prize is a prize awarded by the Finnish Government.
Around 450 proposals for the next awardee were received in a call open to all. The next step for the International Jury is to examine the nominations and propose a recipient. The recipient will be announced at a gala in Tampere on 11 December 2023.
This year's Prize Jury includes human rights activist Zarifa Ghafari, actress Krista Kosonen, news anchor Richard Lui, co-founder and President of GWL Voices Susana Malcorra and CMI - Martti Ahtisaari Peace Foundation’s Chair of the Board Alexander Stubb. The jury is chaired by Saara-Sofia Sirén, President of the National Council of Women of Finland.
Read the full text: https://igep.fi/en/-/zarifa-ghafari-richard-lui-and-susana-malcorra-join-the-prize-jury-2023
Website: www.igep.fi
Photo: Johanna Sokka
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912593136/en/
Contact information
Minna Merikoski
International Affairs Specialist
Phone: +358 40 841 6917
Email: minna.merikoski@tampere.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release
Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen
AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer
Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release
Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent
Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom